AviadoBio Targets Rare Form Of Dementia With Gene Therapy

With Targeted Thalamus Delivery

03 Oct 2022

• By Ayisha Sharma

The UK biotech hopes to address a fast-progressing form of dementia that affects people earlier in life with a supplemental gene therapy delivered directly to the brain’s information centre.

EPC AviadoBio — Frontotemporal Dementia Causes Cognitive, Speech And Behavioral Decline • Source: Shutterstock

AviadoBio Ltd. is preparing to take its lead gene therapy program to the clinic in a subset of dementia patients who could benefit from the greater precision of intra-thalamic delivery.

The firm was spun out of research conducted by neuroscientist Chris Shaw at King’s College, London. Shaw’s team focuses on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eolo Pharma Advances In Obesity With Thermogenesis Approach

04 Jul 2025

• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Immusoft Goes For Cell Therapy Plan ‘B’

26 Feb 2025

• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

29 Nov 2024

• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

01 Nov 2024

• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

09 Jul 2025

• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.